Hepatocellular Carcinoma: The Evolving Treatment Landscape and Cost Utilization Strategies
Tuesday, Nov. 10, 2020, 7-8:30pm ET
Provided by Pharmacy Times Continuing Education.
This activity is supported by an educational grant from Merck Sharp & Dohme Corp.
Continuing education credit available for pharmacists.
Hepatocellular carcinoma (HCC) is the most common form of liver cancer in adults, but symptoms do not typically arise until late in the disease course when prognosis is poor. Until recently, bridging therapies for HCC were limited to select medications, radiation, and arterial-directed therapies until resection or transplantation with a suitable organ. The use of targeted oral and infusional therapies as well as immune checkpoint inhibitors have changed the landscape of HCC treatment. As experts in medication-related education, pharmacists are able to identify barriers to adherence, explain dosing strategies, and manage adverse effects to enhance patient outcomes in HCC. Healthcare resource utilization associated with HCC is increasing due to the growing incidence of disease along with emerging agents in the treatment paradigm. Managed care professionals must take an active role in formulary decisions and the development of treatment pathways to help optimize patient care while minimizing cost impacts.
Pharmacy Times Continuing Education